The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor cancers.

An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease symptoms and duration, according to an animal study published in the

Modernas new cancer vaccine, mRNA-4359, shows promising results in early clinical trials. Utilizing mRNA technology, similar to its Covid-19 vaccine, this treatment primes the immune system to identify and destroy cancer cells.

A new mRNA vaccine developed by Moderna has shown potential in stimulating the immune system to fight advanced cancer, according to results from an initial trial. The vaccine, called mRNA-4359, is designed for patients with advanced melanoma,

A new cancer vaccine could stop tumours growing in patients with advanced disease, researchers say. Designed to prime the body to recognize and fight cancer cells, the jab could stimulate the immune system to treat the deadly disease more effectively,

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer killing cells.

The vaccine, named mRNA-4359, was developed by Moderna and is aimed at people with advanced melanoma, lung cancer, and a range of other solid tumor cancers